Restore Vision

Executive Summary

Restore Vision is a Japanese biotechnology startup pioneering gene-agnostic therapies for inherited retinal diseases, with a lead program RV-001 targeting retinitis pigmentosa (RP). RP is a leading cause of blindness, often caused by mutations in any of over 60 genes; current treatments are limited. RV-001 employs a gene-agnostic approach designed to restore visual function regardless of the underlying mutation, addressing a significant unmet need. The company, founded in 2020 and based in Tokyo, has advanced RV-001 into Phase 1 clinical trials, with initial safety and efficacy data anticipated. Its platform has potential applicability to other retinal degenerations, positioning Restore Vision as a notable player in ophthalmic gene therapy. With a lean team of 10–50 employees, the company leverages Japan’s strong biotech ecosystem and regulatory pathways for rare diseases. Success could provide a first-in-class therapy for a large patient population globally, though proof-of-concept in humans remains to be established.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim safety and efficacy data readout65% success
• Q4 2026Completion of Phase 1 enrollment80% success
• Q2 2027Strategic partnership or licensing deal for Asian markets40% success